Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Trial of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Subjects With Hematologic Malignancies (KEYNOTE-155).

NCT02684617 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT02684617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02684617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Trial of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Subjects With Hematologic Malignancies (KEYNOTE-155).
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1
Overall status
Terminated
Start date
March 29, 2016
Completion date
April 6, 2020
Enrollment
75 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rrcll, rrdlbcl, rrmm